Replies to post #170484 on Biotech Values

[jq1234]

CBST/CXA201 in cUTI: It is actually superior to levofloxacin even though it is a non-inferiority trial, 95% CI = 2.3%, 14.6%.

Result from another ph3 in cIAI will be in late Dec.